| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3247 | 2019 |
| Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ... JAMA oncology 4 (5), e180013-e180013, 2018 | 1707 | 2018 |
| Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial BC Carthon, JD Wolchok, J Yuan, A Kamat, DS Ng Tang, J Sun, G Ku, ... Clinical Cancer Research 16 (10), 2861-2871, 2010 | 553 | 2010 |
| Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival GY Ku, J Yuan, DB Page, SEA Schroeder, KS Panageas, RD Carvajal, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 496 | 2010 |
| CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit J Yuan, S Gnjatic, H Li, S Powel, HF Gallardo, E Ritter, GY Ku, ... Proceedings of the National Academy of Sciences 105 (51), 20410-20415, 2008 | 417 | 2008 |
| Genetic predictors of response to systemic therapy in esophagogastric cancer YY Janjigian, F Sanchez-Vega, P Jonsson, WK Chatila, JF Hechtman, ... Cancer discovery 8 (1), 49-58, 2018 | 333 | 2018 |
| First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial YY Janjigian, SB Maron, WK Chatila, B Millang, SS Chavan, C Alterman, ... The Lancet Oncology 21 (6), 821-831, 2020 | 312 | 2020 |
| Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience GY Ku, BD Minsky, VW Rusch, M Bains, DP Kelsen, DH Ilson Annals of oncology 19 (3), 533-537, 2008 | 155 | 2008 |
| EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer F Sanchez-Vega, JF Hechtman, P Castel, GY Ku, Y Tuvy, H Won, CJ Fong, ... Cancer discovery 9 (2), 199-209, 2019 | 136 | 2019 |
| Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer BA Vellayappan, YY Soon, GY Ku, CN Leong, JJ Lu, JCS Tey Cochrane Database of Systematic Reviews, 2017 | 124 | 2017 |
| Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma J Yuan, GY Ku, HF Gallardo, F Orlandi, G Manukian, TS Rasalan, Y Xu, ... Cancer immunity 9 (1), 2009 | 118 | 2009 |
| Depression, cytokines, and pancreatic cancer W Breitbart, B Rosenfeld, K Tobias, H Pessin, GY Ku, J Yuan, J Wolchok Psycho‐oncology 23 (3), 339-345, 2014 | 111 | 2014 |
| Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma RJ Kelly, J Lee, YJ Bang, K Almhanna, M Blum-Murphy, DVT Catenacci, ... Clinical Cancer Research 26 (4), 846-854, 2020 | 104 | 2020 |
| A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. O Insug, G Ku, HC Ertl, M Blaszczyk-Thurin Anticancer research 22 (2A), 613-621, 2002 | 104 | 2002 |
| Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials GY Ku, BA Haaland, G de Lima Lopes Jr Lung Cancer 74 (3), 469-473, 2011 | 100 | 2011 |
| Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience DC Glassman, RL Palmaira, CM Covington, AM Desai, GY Ku, J Li, ... BMC cancer 18 (1), 1-10, 2018 | 92 | 2018 |
| Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012 G Ku, IBH Tan, T Yau, N Boku, S Laohavinij, AL Cheng, YK Kang, ... The lancet oncology 13 (11), e470-e481, 2012 | 91 | 2012 |
| Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer M Greally, JF Chou, WK Chatila, M Margolis, M Capanu, JF Hechtman, ... Clinical cancer research 25 (20), 6160-6169, 2019 | 87 | 2019 |
| Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer DH Ilson, BD Minsky, GY Ku, V Rusch, N Rizk, M Shah, DP Kelsen, ... Cancer 118 (11), 2820-2827, 2012 | 87 | 2012 |
| Esophagogastric cancer: targeted agents GY Ku, DH Ilson Cancer treatment reviews 36 (3), 235-248, 2010 | 82 | 2010 |
David IlsonProfessor of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center在 mskcc.org 的电子邮件经过验证
